Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
GP4-V15223 | HIV-1 (CM244) | HIV-1 [HIV-1/Clade E (CM244)] GP120 Protein, His Tag |
|
||
GP5-V15224 | HIV-1 (16055) | HIV-1 [HIV-1/Clade C (16055)] GP120 Protein, His Tag |
|
||
GP4-V15227 | HIV-1 (CN54) | HIV-1 [HIV-1/Clade B/C (CN54)] GP120 Protein, His Tag (MALS verified) |
|
Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 2 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade C (16055)] GP120, His Tag (Cat. No. GP5-V15224) with a linear range of 0.5-63 ng/mL (QC tested).
The purity of HIV-1 [HIV-1/Clade B/C (CN54)] GP120, His Tag (Cat. No. GP4-V15227) is more than 90% and the molecular weight of this protein is around 90-120 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.